Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) FCF Margin (2018 - 2025)

Historic FCF Margin for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to 48.86%.

  • BioNexus Gene Lab's FCF Margin rose 196500.0% to 48.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 29.17%, marking a year-over-year increase of 66700.0%. This contributed to the annual value of 25.88% for FY2024, which is 57000.0% down from last year.
  • Per BioNexus Gene Lab's latest filing, its FCF Margin stood at 48.86% for Q3 2025, which was up 196500.0% from 33.6% recorded in Q2 2025.
  • In the past 5 years, BioNexus Gene Lab's FCF Margin registered a high of 16.19% during Q4 2022, and its lowest value of 68.52% during Q3 2024.
  • In the last 5 years, BioNexus Gene Lab's FCF Margin had a median value of 4.91% in 2023 and averaged 15.24%.
  • Its FCF Margin has fluctuated over the past 5 years, first plummeted by -512600bps in 2023, then surged by 374100bps in 2024.
  • Quarter analysis of 5 years shows BioNexus Gene Lab's FCF Margin stood at 14.84% in 2021, then increased by 9bps to 16.19% in 2022, then tumbled by -313bps to 34.47% in 2023, then skyrocketed by 109bps to 2.94% in 2024, then crashed by -1762bps to 48.86% in 2025.
  • Its last three reported values are 48.86% in Q3 2025, 33.6% for Q2 2025, and 38.98% during Q1 2025.